Shots:

• The companies will utilize Celularity's CYNK-001 as a potential novel therapy for the treatment and prevention of coronaviruses targeting mainly 2019-nCoV
• Sorento will utilize its existing “state-of-the-art” cGMP cell therapy manufacturing facilities in California to augment Celularity's new cGMP facility in New Jersey. The combined capacity will boost the scale-up and sustained production of the novel cell therapy
• Celularity's CYNK-001 is an allogeneic- off-the-shelf- placental-derived NK cell therapy. Additionally- Sorrento is in contact with scientists and local Chinese experts to discuss the clinical validation and logistics requirements to fast-track CYNK-001 available in China for coronavirus infection

Click here ­to­ read full press release/ article | Ref: Sorrento Therapeutics | Image:  Sorrento Therapeutics